SVB Leerink maintained its Regenxbio [RGNX] rating to the equivalent of Market Perform but changed the price target to $37 from $34, in a research note dated 2021-01-06. That figure represents around a -17.61% premium from where the company’s shares closed on Tuesday. In addition, RBC Capital Mkts launched coverage on May 13, 2020. The research firm rated RGNX “a Sector perform”.
Is REGENXBIO Inc. [NASDAQ:RGNX] a Good Buy Right Now?
It should be noted that RGNX technical indicators for short, intermediate as well as long term progress have placed an overall average of 88% as Buy. The average signal changed from 88% Buy in the last week and compares with 40% Buy in the past month. Data from REGENXBIO Inc.’s Trend Spotter indicated that the signals were Weakest. The stock current average is 0.45 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 0.38 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 50% Buy and the 100-day average volume stands at 0.37 million shares.
RGNX Price Performance
On Wall Street, REGENXBIO Inc. [NASDAQ:RGNX] finished Tuesday’s session down -0.13% at $44.91. The stock went up to $45.75 at the same session while its lowest single day price was $44.33. In the last five days, it saw a fall of about -6.24%, REGENXBIO Inc. shares dropped by almost -0.99% since the beginning of the year. However, the share price has dropped to as low as -18.30% below its one year high. On 01/04/21, the company shares recorded $46.03, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $44.16. The company’s shares have inclined by 12.16% in the past year. The 50-day SMA achieved is $37.53 while the 200-day SMA is $34.93. Volume dropped to 0.22 million from 0.32 million in the previous session.
RGNX Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 44.24 level, and in case of violation of this particular level, it will cause more drop to 43.58 level. On the upper level, 46.42 is still the key resistance. The stock may increase to the subsequent resistance at 45.66. The Relative Strength Index (RSI) pinned on the 14-day chart is 60.06, implying a neutral technical stance while the MACD stands at -0.98, meaning price will decrease in the next trading period. Percent R indicator moved to 54.30%, implying low price movement. Stochastic %K at 52.07% suggest selling the stock.
What is the short interest in REGENXBIO Inc.?
Short interest in the REGENXBIO Inc. stock has surged, increasing by 0.54 million shares to total 3.29 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 3.83 million, data from Yahoo Finance shows. The decrease of -16.41% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 13.94% of the overall float for the stock.
REGENXBIO Inc.’s Biggest Shareholders: Who Owns REGENXBIO Inc. [RGNX]?
Filings by BlackRock Fund Advisors showed that the firm now holds a total of 4,854,230 shares or roughly 12.98% of the outstanding RGNX shares. This means their shares have reduced by -68,420 from the 4,854,230 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, The Vanguard Group, Inc. updated stake is worth $109,701,265. Details in the latest 13F filings reveal that Redmile Group LLC disposed off their -0.38% stake valued at $77,629,303 while SSgA Funds Management, Inc. cut theirs at $74,693,371. During the last quarter, Redmile Group LLC liquidated -8,600 of its shares in REGENXBIO Inc. while SSgA Funds Management, Inc. sold -101,743 shares. The GIC Pte Ltd.’s holdings currently number 2,080,352 shares at $93428608.32. According to the firm’s last 13F report, JPMorgan Investment Management, I shares in the company at filing stood at 912,936 shares, roughly $31,806,690.
RGNX Earnings Forecast For The Current Quarter
REGENXBIO Inc. [RGNX] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $63.59M and an earnings per share of -$0.33 for Dec 2020. Looking further ahead, the company is expected to report revenue of $29.54M at an EPS of -$0.89 for Mar 2021. The estimates represent upside of -20.60% and -89.40% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
RGNX Earnings Estimates For The Current Year
For the financial year, REGENXBIO Inc. [NASDAQ:RGNX] is expected to bring in revenue of $186.28M. The returns are nearly $151.05 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -2.08, higher than that of FY19 by $0.5. Estimates put this year’s earnings growth at 19.40%, -89.40% for the next, and at an annual 2.00% over the next 5-year period. As for sales, forecasts are for an increase of 428.70% in the current fiscal year and a further -20.60% over the following year.